3/13/2023 | EMHYLM | Teva gives results, ups caps in offer for $2.5 billion of notes
|
3/6/2023 | BKCVEMHY | S&P assigns BB- to Teva notes
|
3/3/2023 | BKCVDDEMIGPV | Market Commentary: Junk secondary strengthens; Navacord tucked away; Frontier lifted; Teva moves higher
|
3/3/2023 | HY | Market Commentary: Junk secondary strengthens; Navacord tucked away; Frontier lifted; Teva moves higher
|
3/2/2023 | BKCVDDEMIGPV | Market Commentary: Jones DesLauriers prices; Teva, Ritchie, Alteryx at premiums; junk funds out $2.31 billion
|
3/2/2023 | HY | Market Commentary: Jones DesLauriers prices; Teva, Ritchie, Alteryx at premiums; junk funds out $2.31 billion
|
3/2/2023 | HY | Market Commentary: Morning Commentary: Ranger Oil jumps on acquisition news; junk funds track outflows
|
3/1/2023 | EMGNHY | New Issue: Teva prices upsized $2.49 billion equivalent sustainability notes in four tranches
|
3/1/2023 | BKCVEMGNHY | Fitch assigns BB- to Teva notes
|
3/1/2023 | EMGNHY | Teva upsizes to $2.49 billion, hones talk on four-part notes offering; pricing Wednesday
|
2/28/2023 | EMGNHY | Moody's assigns Ba2 to Teva notes
|
2/28/2023 | EMGNHY | Teva sets talk in $2.06 billion four-part sustainability-linked notes offering; pricing Wednesday
|
2/27/2023 | EMHYLM | Teva starts tender offer for $2.25 billion of notes due 2023 to 2026
|
2/27/2023 | EMGNHY | Teva starts roadshow for $2.06 billion four-part offering of sustainability-linked notes
|
2/24/2023 | EMHY | Israel’s Teva sets non-deal roadshow via Citigroup and Goldman Sachs in week ahead
|
11/10/2021 | EMHYLM | Teva gives early tender results for six series, lifts cap to $4 billion
|
10/27/2021 | EMHYLM | Teva Pharmaceutical commences capped cash tender offer for six series of notes
|
10/27/2021 | EMHY | S&P assigns Teva notes BB-
|
10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes; pricing expected Tuesday
|
10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes
|
10/27/2021 | EMHY | Moody's rates Teva notes Ba2
|
11/25/2019 | DDEMHYLM | Teva gives early results for tenders for 2.2%, 3.65% notes due 2021
|
11/19/2019 | HY | Market Commentary: Teva, Houghton Mifflin, Sinclair, Kaiser Aluminum, Allegheny price; iHeart, Boyd weaken
|
11/19/2019 | EMHY | New Issue: Teva Pharmaceutical prices $1 billion 7 1/8% notes and €1 billion 6% notes at par
|
11/19/2019 | EMHY | Teva Pharmaceutical upsizes bond tranches, tightens talk amid huge demand; pricing Tuesday
|
11/19/2019 | EMHY | Teva Pharmaceutical ups bond tranches to $1 billion and €1 billion, tightens talk; pricing Tuesday
|
11/18/2019 | HY | Market Commentary: iHeart, Boyd, Mattel, MSCI add-on price; Prestige Brands, Univar, Maxar trade up; Intelsat sinks
|
11/18/2019 | EMHY | Teva sets tranches, talk for upsized $2 billion equivalent long five-year dual-currency notes
|
11/14/2019 | BKCVEM | Moody’s rates Teva notes Ba2
|
11/8/2019 | HY | Market Commentary: Teva rises after starting tender offers; Revlon notes head lower following earnings
|
11/8/2019 | DD | Market Commentary: Teva rises after starting tender offers; Revlon notes head lower following earnings
|
11/8/2019 | DDEMHYLM | Teva tenders for 2.2%, 3.65% notes, will spend up to $1.5 billion
|
3/16/2018 | BKCVEMIG | Fitch rates Teva Pharmaceutical notes BB/RR4
|
3/8/2018 | HY | Market Commentary: Frontier, Springleaf lead year’s busiest day; new issues busy; funds lose $525 million
|
3/1/2018 | BKCVEMIG | Fitch rates Teva notes BB
|
2/28/2018 | BKCVEM | S&P rates Teva notes BB
|
2/28/2018 | BKCVEM | Moody’s applies Ba2 to Teva notes
|
11/3/2017 | IG | Market Commentary: Morning Commentary: Primary quiet; secondary volume strong; Teva weakens on earnings warning
|
8/11/2017 | IG | Market Commentary: Morning Commentary: Primary market quiet; Lear eyes note offering; Teva trades heavily
|
12/30/2016 | IG | Market Commentary: Outlook 2017: High-grade supply to stay robust; bond views mixed; mergers remain on forefront
|
8/1/2016 | EMHYMUPFPV | Market Commentary: Microsoft, Synchrony, Consumers Energy, Tanger price; Microsoft, Procter & Gamble ease
|
8/1/2016 | IG | Market Commentary: Microsoft, Synchrony, Consumers Energy, Tanger price; Microsoft, Procter & Gamble bonds ease
|
8/1/2016 | IG | Market Commentary: Morning Commentary: Primary environment ‘enticing’; Verizon, Teva soften; Libor yield rises
|
7/22/2016 | EMHYMUPFPV | Market Commentary: Light deal volume forecast; Teva holds tight; Citigroup firms; Morgan Stanley steady
|
7/22/2016 | IG | Market Commentary: Light deal volume forecast; Teva holds tight; Citigroup firms; Morgan Stanley steady
|
7/20/2016 | EMHYMUPFPV | Market Commentary: Primary action thins; Citi subordinated notes mixed; Teva stronger; credit spreads firm
|
7/20/2016 | IG | Market Commentary: Primary action thins; Citigroup subordinated notes mixed; Teva stronger; credit spreads firm
|
7/20/2016 | IG | Market Commentary: Morning Commentary: Teva notes tighten; Citigroup paper unchanged; Libor yield hits 70 bps
|
7/19/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
7/18/2016 | IG | Market Commentary: Teva prices $15 billion; Citi, Wells Fargo tap market; bonds mixed; credit spreads improve
|
7/18/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2
|
7/18/2016 | EMIG | Teva Pharmaceuticals in the market with fixed-, floating-rate notes
|